Literature DB >> 23101310

Nasal and bronchial inflammation after nasal allergen challenge: assessment using noninvasive methods.

C D Serrano1, A Valero, J Bartra, J Roca-Ferrer, R Muñoz-Cano, J Sánchez-López, J Mullol, C Picado.   

Abstract

BACKGROUND: Links between the upper and lower airways have been demonstrated in recent years. However, few studies have evaluated inflammation using noninvasive methods.
METHODS: A nasal allergen challenge was performed with pollen outside the pollen season in 30 patients with allergic rhinitis due to pollen but no asthma. Clinical and inflammatory nasal and bronchial responses to nasal allergen challenge were evaluated using the nasal symptoms score (NSS), visual analog scale (VAS), nasal geometry (volume between 2 and 5 cm [Vol2-5]) by acoustic rhinometry, lung function by spirometry, nasal nitric oxide (nNO), and exhaled nitric oxide (eNO). Values were recorded at baseline, 15 minutes, and 2 and 24 hours after challenge. Nasal lavage and exhaled breath condensate (EBC) samples were collected at 2 and 24 hours to assess 8-isoprostane, cys-leukotrienes, eosinophil cationic protein (ECP), tryptase, granulocyte-macrophage colony-stimulating factor, and interleukin (IL) 5.
RESULTS: NSS and VAS increased significantly at 15 minutes and 2 and 24 hours after challenge. Vol2-5 decreased significantly at 15 minutes and 2 hours, while nNO decreased at 15 minutes. All inflammatory mediators except ECP increased significantly at 2 hours in nasal lavage samples, while ECP, 8-isoprostane, and cys-leukotrienes increased at 24 hours (P < .01). In EBC, 8-isoprostane and cys-leukotrienes increased at 2 and 24 hours (P < .01). No significant changes were found at any time in lung function or eNO.
CONCLUSION: Nasal allergen challenge induces clinical and inflammatory responses in the nose and bronchi that can be assessed using noninvasive methods such as nasal lavage, EBC, and nNO.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23101310

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  7 in total

1.  [The NTP in allergy research : open questions regarding nasal provocation tests using allergens].

Authors:  U Förster; A Sperl; L Klimek
Journal:  HNO       Date:  2013-10       Impact factor: 1.284

2.  Effect of obesity on sinonasal disease in asthma.

Authors:  S Kanagalingam; S S Shehab; D A Kaminsky; R A Wise; J E Lang; A E Dixon
Journal:  J Asthma       Date:  2017-07-31       Impact factor: 2.515

Review 3.  A Review of the Respiratory Health Burden Attributable to Short-Term Exposure to Pollen.

Authors:  Nur Sabrina Idrose; Caroline J Lodge; Bircan Erbas; Jo A Douglass; Dinh S Bui; Shyamali C Dharmage
Journal:  Int J Environ Res Public Health       Date:  2022-06-20       Impact factor: 4.614

Review 4.  The Utility of Nasal Challenges to Phenotype Asthma Patients.

Authors:  Guillermo Bentabol-Ramos; Rocio Saenz de Santa Maria-Garcia; Monica Vidal-Diaz; Ibon Eguiluz-Gracia; Almudena Testera-Montes
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

5.  Leukotriene D4 nasal provocation test: Rationale, methodology and diagnostic value.

Authors:  Zheng Zhu; Yanqing Xie; Weijie Guan; Y I Gao; Shu Xia; Jianxin Liang; Jinping Zheng
Journal:  Exp Ther Med       Date:  2016-05-10       Impact factor: 2.447

6.  Functional significance of 8-isoprostanes in sinonasal disease and asthma.

Authors:  Brittany Duchene; Sarah Caffry; David A Kaminsky; Loretta G Que; Matthew E Poynter; Anne E Dixon
Journal:  Respir Med       Date:  2021-06-09       Impact factor: 4.582

7.  Eosinophil-related markers and total immunoglobulin E as a predictive marker for antibiotic response in chronic rhinosinusitis.

Authors:  Youn Ho Shin; Hwan Soo Kim; Eu Kyoung Lee; Young Joo Kim; Hyun-Seung Lee; Pil-Sang Jang; Young-Hoon Kim; Yoon Hong Chun; Jong-Seo Yoon; Hyun Hee Kim; Young-Yull Koh; Jin Tack Kim
Journal:  Ann Saudi Med       Date:  2015 Jul-Aug       Impact factor: 1.526

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.